Evenity Injection, Solution
Product Images NDC 55513-880

5 FDA label images from Amgen, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Evenity (NDC 55513-880). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Syringe (Evenity 01)

Syringe (Evenity 01)
An instructional diagram illustrating a syringe labeled with components including a gray needle cap, syringe barrel containing medicine, label and expiration date on the barrel, finger flange, and plunger rod, showing an injection device assembly.*
FDA Label Image

Prepare And Clean Two Injection Sites, One For Each Of The Two Injections. See Figure B. (Evenity 02)

Prepare And Clean Two Injection Sites, One For Each Of The Two Injections. See Figure B. (Evenity 02)
An illustration showing recommended injection sites for a subcutaneous injection of Evenity (romosozumab-aqqg). The diagram highlights the upper arm, abdomen, and thigh areas on a human figure as suitable sites for administration.*
FDA Label Image

Figure C (Evenity 03)

Figure C (Evenity 03)
An instructional diagram showing two hands demonstrating a medical injection preparation technique. The top hand holds a vial inverted with an arrow indicating upward motion; the bottom hand holds a syringe drawing liquid from the vial, labeled as Figure C.*
FDA Label Image

Figure D (Evenity 04)

Figure D (Evenity 04)
Instructional illustration showing a hand administering a subcutaneous injection with a syringe or pen into the skin, demonstrating the proper injection technique. Labeled as Figure D.*
FDA Label Image

Principal Display Panelpdp Image And Text_evenity_pfs_ndc 55513-8802 X 105 mg/1.17 mL Singe-use Prefilled Syringendc 55513-880-02evenity™ (romosozumab-aqqg)injectionfor Healthcare Provider Use Only105 mg/1.17 mL + 105 mg/1.17 mL = 1 Dose 210 mg/2.34 mL2 X 105 mg/1.17 mL105 mg/1.17 mLfor Subcutaneous Use Onlysterile Solution – No Preservativestore Refrigerated At 2°c To 8°c (36°f To 46°f). Do Not Freeze Or Shake.store In Carton To Protect From Light.keep Out Of The Sight And Reach Of Children.attention: Provide The Enclose Medicationguide To Each Patient. For More Copiessee Evenity.com Or Call 1-800-77amgen.2 Syringes Must Be Administered Fora Full 210 mg/2.34 mL Doserx Onlyamgen® Ucb (Evenity 06)

Principal Display Panelpdp Image And Text_evenity_pfs_ndc 55513-8802 X 105 mg/1.17 mL Singe-use Prefilled Syringendc 55513-880-02evenity™ (romosozumab-aqqg)injectionfor Healthcare Provider Use Only105 mg/1.17 mL + 105 mg/1.17 mL = 1 Dose 210 mg/2.34 mL2 X 105 mg/1.17 mL105 mg/1.17 mLfor Subcutaneous Use Onlysterile Solution – No Preservativestore Refrigerated At 2°c To 8°c (36°f To 46°f). Do Not Freeze Or Shake.store In Carton To Protect From Light.keep Out Of The Sight And Reach Of Children.attention: Provide The Enclose Medicationguide To Each Patient. For More Copiessee Evenity.com Or Call 1-800-77amgen.2 Syringes Must Be Administered Fora Full 210 mg/2.34 mL Doserx Onlyamgen® Ucb (Evenity 06)
Evenity 105 mg/1.17 mL injection solution label for subcutaneous use by Amgen, Inc. The label shows two single-use prefilled syringes each containing 105 mg/1.17 mL for a total dose of 210 mg/2.34 mL. It includes storage instructions, warnings, and visual dosage representation. The label is marked for healthcare provider use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.